Phase II Study of VCD/IE in the Treatment of the Patients With Ewing's Sarcoma Family of Tumors
80-90% patients of ESFT will develope disease progression during the period of local
treatment (surgery or radiation). The survival has been improved in these 30 years due to
chemotherapy. VCD/IE is widely used in the world for the patients with ESFT, but it is
rarely used in China due to its high dosage.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
every two cycles
Ye Guo, M.D.
China: Ethics Committee